



PEPTIDE THERAPEUTICS FORUM 2016

Chairs T. Vorherr, Novartis Pharma AG, Basel CH
E. Kitas, Roche Innovation Center, Basel CH
R. Stocklin, Atheris SA, Geneva CH

Congress Center Basel

Messeplatz 21, 4021 Basel, CH

www.basellife.org

Tuesday, 20 September 2016 / 9.15 – 17.15

Opportunities for chemical protein mimics in vaccine design

R. Liskamp, University of Glasgow, Glasgow UK

Targeting peptides versus proteins by vaccination: size matters

M. Bachmann, Inselspital, Bern CH

A Chemical Space Approach to Discover Novel Antimicrobial Peptides

J-L. Reymond, University of Bern, Bern CH

Specific inhibition of beta-secretase processing of the Alzheimer's disease amyloid precursor protein

L. Rajendran, University of Zurich CH

Brain Shuttle targeting Antibody coupled to peptide-based payloads

E. Kitas, F. Hoffmann-La Roche, Basel CH

Recent advances in solid phase peptide synthesis

Dr. Peter White, Merck, Nottingham UK

Enabling methods for the rapid total chemical synthesis of proteins

O. Seitz, Humboldt University Berlin DE

Function of human type sialyloligosaccharide for the bioactivity of glycoproteins

Y. Kajihara, University of Osaka, JP

Wednesday, 21 September 2016 / 9.15 – 17.15

Making connections in peptide chemistry

P. Dawson, The Scripps Research Institute, La Jolla US

Chemical Biology of Peptide Natural Products - Structures, Syntheses and Bioactivities

R. Süßmuth, TU Berlin DE

Oxytocin Mimetics

P. Alewood, The University of Queensland, Brisbane, AU

Therapeutic Potential of Conus Venom Peptides

B. Olivera, University of Utah, Salt Lake City, US

Knottins and beyond: mono- and oligovalent constrained peptide inhibitors for biomedical applications

H. Kolmar, TU Darmstadt, Darmstadt DE

The challenges of targeting RXFP1, the receptor for the heart failure drug candidate Relaxin-2, with peptide mimetics and small molecules

R. Bathgate, Florey Neuroscience Institutes, Parkville AU

The influence of stabilization of peptide therapeutics on their immunogenic potential

T. Schwandt, Roche Innovation Center, Basel CH

XTEN™ Protein Polymer for Half-Life Extension and Tumor Drug Delivery

V. Schellenberger, Amunix, Mountainview US